This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: What's the potential of NMTR's Vurolenatide in short bowel syndrome?

Ticker(s): NMTR, TAK

Who's the expert?

Institution: University of Alberta

  • Assistant Clinical Professor Department of Medicine Division of Gastroenterology at University of Alberta.
  • Manages 75 patients with short bowel disease.
  • Medical lead for Nutrition Services for the northern zone of Alberta.

Interview Questions

Roughly how many patients with SBS do you currently manage?

Added By: c_admin

On a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for Vurolenatide?

Added By: c_admin

Do you view vurolenatide as better for patients than Gattex?

Added By: edsitar

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.